Vedanta Biosciences, is a microbiome company and designs medicines based on consortia of human commensal bacteria and is founded by PureTech Ventures. Vedanta Biosciences has isolated, characterized and maintains the largest collection of human microbiome-associated bacterial strains. Vedanta to generate a pipeline of programs addressing infectious diseases, autoimmune diseases, inflammation and immune-oncology indications.
Vedanta Biosciences, Inc.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/vedanta-biosciences-inc-” connections=”true” suffix=””]
Vedantas technology platform enables identification of defined bacterial consortia with drug-like properties and their manufacture to GMP standards.
In Mar 2016, Vedanta acquired exclusive rights to key intellectual property based on Dr. Kenya Hondas discoveries, from JSR Corporation, Japan, on development of advance cancer Immunotherapy candidates based on Microbiome-derived live biotherapeutics, which have been shown to activate CD8+ T cells. An IND filing for the lead product candidate is planned in 2018.
In Nov 2017, Vedanta Biosciences recieved a funding of $5.4 Mn from CARB-X to support the development of a novel, human microbiome-derived treatment for the prevention of bacterial infections caused by C. difficile.
In Jun 2016, Vedanta Biosciences recieved $50 Mn in new equity financing. Rock Springs Capital, Invesco IVZ Asset Management, Health for Life Capital and PureTech joined the financing.